A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer

2013255 citationsJournal Articlebronze Open Access

Authors

Amanda Eustace · Cancer Research UK Manchester Institute

Navin Mani · MRC Weatherall Institute of Molecular Medicine

Paul N. Span · Radboud University Nijmegen

Joely J. Irlam · Cancer Research UK Manchester Institute

Janet Taylor · University of Oxford

Guy Betts · Mount Vernon Hospital

Helen Denley

Abstract

The 26-gene hypoxia signature predicts benefit from hypoxia-modifying treatment in laryngeal cancer. These findings will be evaluated in a prospective clinical trial.

Topics & Keywords

Cancer, Hypoxia, and Metabolism Cancer-related molecular mechanisms research RNA modifications and cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 19, Issue 17, pp. 4879-4888

DOI: 10.1158/1078-0432.ccr-13-0542

Field-Weighted Citation Impact: 4.08